NCNelson Côrtes

Nelson Côrtes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nelson Côrtes has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    COVID-19 vaccination atlas: an integrative systems vaccinology approach

    by Gustavo Cabral-Miranda, Wasim Prates-Syed, Dennyson Fonseca, Shahab Pour, Lena Schimke, Aline Lira, Nelson Côrtes, Jaqueline Silva, Evelyn Carvalho, Igor Filgueiras, et al.

    The COVID-19 vaccinations have played a significant role in controlling the pandemic. To elucidate their impact on the immune system, a COVID-19 vaccination atlas was developed through an integrative systems vaccinology approach. The atlas includes both healthy individuals and those infected with or without prior vaccination, and covers the administration of five vaccines in different regimens: Covilo®, Zifivax®, Vaxzebria® or Covishield®, Spikevax®, and Comirnaty®. Critical markers were identified to discriminate the different types of vaccines and infection, in which infection was associated with GATA3, ZNF3, KMT2A, ASXL1, SP100, and GZMM, and vaccine types were marked by ITGAM, ACTG1, LGALS3, and STAT5B. Additionally, the immunological signatures of heterologous vaccination and infection were described, and it was also shown how a full vaccination regimen markedly limited the shift of immune responses during natural infection, thereby constraining disease progression. Finally, the common transcripts shared across COVID-19 vaccines and vaccines against other pathogens were described.

  • Open Access

    COVID-19 vaccination atlas: an integrative systems vaccinology approach

    by Wasim Aluísio Prates-Syed, Dennyson Leandro M Fonseca, Shahab Zaki Pour, Igor Salerno Filgueiras, Lena F Schimke, Aline Aparecida Lira, Nelson Cortes de Oliveira, Jaqueline Dinis Queiroz Silva, Evelyn Carvalho, Tania Geraldine Churasacari-Vinces, et al.

    The COVID-19 vaccinations have played a significant role in controlling the pandemic. To elucidate their impact on the immune system, a COVID-19 vaccination atlas was developed through an integrative systems vaccinology approach. The atlas includes both healthy individuals and those infected with or without prior vaccination, and covers the administration of five vaccines in different regimens: Covilo®, Zifivax®, Vaxzebria® or Covishield®, Spikevax®, and Comirnaty®. Critical markers were identified to discriminate the different types of vaccines and infection, in which infection was associated with GATA3, ZNF3, KMT2A, ASXL1, SP100, and GZMM, and vaccine types were marked by ITGAM, ACTG1, LGALS3, and STAT5B. Additionally, the immunological signatures of heterologous vaccination and infection were described, and it was also shown how a full vaccination regimen markedly limited the shift of immune responses during natural infection, thereby constraining disease progression. Finally, the common transcripts shared across COVID-19 vaccines and vaccines against other pathogens were described.


  • Open Access

    Vaccines against Emerging and Neglected Infectious Diseases: An Overview

    by Larissa Vuitika, Wasim A. Prates-Syed, Jaqueline Dinis Queiros Silva, Karin P. Crema, Nelson Côrtes, Aline Lira, Julia Beatriz Menuci Lima, Niels Olsen Saraiva Camara, Lena F. Schimke, Otavio Cabral-Marques, et al.

    Neglected Tropical Diseases (NTDs) are a group of diseases that are highly prevalent in tropical and subtropical regions, and closely associated with poverty and marginalized populations. Infectious diseases affect over 1.6 billion people annually, and vaccines are the best prophylactic tool against them. Along with NTDs, emerging and reemerging infectious diseases also threaten global public health, as they can unpredictably result in pandemics. The recent advances in vaccinology allowed the development and licensing of new vaccine platforms that can target and prevent these diseases. In this work, we discuss the advances in vaccinology and some of the difficulties found in the vaccine development pipeline for selected NTDs and emerging and reemerging infectious diseases, including HIV, Dengue, Ebola, Chagas disease, malaria, leishmaniasis, zika, and chikungunya.


  • Open Access

    VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants

    by Wasim A. Prates-Syed, Lorena C. S. Chaves, Karin P. Crema, Larissa Vuitika, Aline Lira, Nelson Côrtes, Victor Kersten, Francisco E. G. Guimarães, Mohammad Sadraeian, Fernando L. Barroso da Silva, et al.

    Virus-like particles (VLPs) are a versatile, safe, and highly immunogenic vaccine platform. Recently, there are developmental vaccines targeting SARS-CoV-2, the causative agent of COVID-19. The COVID-19 pandemic affected humanity worldwide, bringing out incomputable human and financial losses. The race for better, more efficacious vaccines is happening almost simultaneously as the virus increasingly produces variants of concern (VOCs). The VOCs Alpha, Beta, Gamma, and Delta share common mutations mainly in the spike receptor-binding domain (RBD), demonstrating convergent evolution, associated with increased transmissibility and immune evasion. Thus, the identification and understanding of these mutations is crucial for the production of new, optimized vaccines. The use of a very flexible vaccine platform in COVID-19 vaccine development is an important feature that cannot be ignored. Incorporating the spike protein and its variations into VLP vaccines is a desirable strategy as the morphology and size of VLPs allows for better presentation of several different antigens. Furthermore, VLPs elicit robust humoral and cellular immune responses, which are safe, and have been studied not only against SARS-CoV-2 but against other coronaviruses as well. Here, we describe the recent advances and improvements in vaccine development using VLP technology.